IXJ, the iShares Global Healthcare ETF, continues to face relative underperformance against its U.S.-focused peer XLV (Health Care Select Sector SPDR). This divergence reflects a structural headwind: international healthcare exposure is not keeping pace with domestic market strength, suggesting either currency headwinds, valuation compression in non-U.S. markets, or divergent regulatory environments dampening global healthcare returns.
The long-term and short-term underperformance pattern indicates this is not a temporary drawdown but rather a persistent competitive disadvantage. XLV's outperformance likely stems from concentration in mega-cap U.S. pharma and medical device leaders with pricing power and earnings stability, while IXJ's global mandate dilutes exposure to higher-growth or higher-margin segments within developed markets.
For portfolio construction, this comparison highlights a critical decision point: domestic healthcare concentration versus international diversification. IXJ holders face pressure to justify geographic diversification when domestic healthcare equities deliver superior risk-adjusted returns, particularly in volatile macro environments where currency risk adds friction.
Sector implication: Healthcare remains a defensive, earnings-resistant sector, but regional performance gaps signal that sector rotation decisions now depend heavily on geographic positioning. U.S. healthcare exceptionalism—driven by pricing leverage and market structure—continues to widen the performance gap versus ex-U.S. developed healthcare exposure.